Rosier Picture Of Life After Prostate Surgery

June 05, 1997

Every man considering surgery for treatment of prostate cancer knows he could leave the hospital incontinent and impotent. Some men with prostate cancer fear these complications so much they avoid surgery altogether, even though it's the surest method to rid the body of cancer. But perhaps these men should reconsider their options. According to a new study by researchers at Washington University School of Medicine in St. Louis, today's prostate cancer patients recover remarkably well from surgery, and very few regret having the operation.

The researchers surveyed more than 1,000 prostate cancer patients and found that men who opted for surgery compared favorably to men who underwent other treatments. "The surgery patients fared well emotionally, they adjusted well, and very few reported being dissatisfied with their treatment," says Deborah S. Smith, Ph.D., research assistant professor of urologic surgery and lead researcher for the study, which was funded by the American Cancer Society.

Although surgery did put men at a higher risk for sexual problems, it didn't increase the risk of incontinence. Most importantly, the men who underwent surgery felt healthier than the other patients and were just as content with their lives.

The researchers reported their findings April 16, 1997, at the annual meeting of the American Urological Association in New Orleans. "This is the first modern study to look at outcomes for men whose prostate cancer was detected through screening," says William Catalona, M.D., chief of urologic surgery at the School of Medicine and co-researcher of the study. "The results are far more encouraging than anything else that has been published."

Surveys Yield Surprises

The researchers sent surveys to 1,842 men who had been diagnosed with prostate cancer through screening at the Washington University School of Medicine between 1989 and 1995. They eventually received 1,340 completed surveys. Seventy-six percent of the respondents had undergone radical prostate removals at the School of Medicine and elsewhere; 18 percent had received treatments of hormones, radiation or cryotherapy; and 6 percent had received no treatment.

The questionnaires asked the men if their current urinary or sexual functioning "bothered" them. The men also rated their satisfaction with their treatment, their overall emotional well-being and their general health. About 58 percent of surgery patients reported problems with sexual functioning, compared with 51 percent of the patients who had other therapies and 35 percent who had no treatment. "That's a striking difference, but it's smaller than we expected," Smith says.

Surprisingly, the percentage of patients reporting urinary problems was the same for each group -- about 10 percent. "We thought the surgery patients would be most bothered by urinary problems because that is a potential side effect of surgery," Smith says. A recent study of Medicare patients showed that 32 percent of the men had to wear pads after surgery for prostate cancer, Smith says. She notes that those patients hadn't necessarily undergone prostate cancer screening and that the cancers may have been relatively advanced at the time of surgery.

Satisfied Patients

About 90 percent of the men in each Washington University survey group said they were satisfied with their treatment.

Interestingly, the major key to satisfaction turned out to be urinary function, not sexual function. Men with urinary problems were generally dissatisfied with their treatment, but men with sexual problems were as satisfied as everyone else.

The groups also were nearly identical in terms of emotional well-being, and their scores were typical for men their age. The surgical patients felt slightly healthier than the other patients, partly because doctors consider healthy men to be the best candidates for prostate cancer surgery.

Smith points out that the average surgery patient was 65 at the time of diagnosis, about seven years younger than the patients in the other two groups. Doctors generally don't recommend surgery for prostate cancer patients in their mid-70s or older because the operation probably won't add significantly to their life span, Smith says. The age difference in the study partially explains why the surgery patients responded so well to treatment, and Smith plans to adjust the results to account for the age gap. She also plans to send out a new batch of surveys this year.

The current picture for prostate surgery patients may be incomplete, but it's decidedly rosier than it used to be, Catalona says. Previous studies had painted a bleak picture of life after the operation, he explains. "Those studies showed gloom and doom -- almost every patient was impotent, incontinent and unhappy," he says. "But those studies are from years ago, when surgeons weren't using modern techniques and cancers weren't detected early. Today, patients have an excellent chance of leading full lives after prostate surgery."

Washington University in St. Louis

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to